SFRP1 and renal cell carcinoma: Early in 2006, Urakami et al. (2006) reported that RCC patients significantly demonstrated high methylation levels of WNT antagonists, including sFRP-1, sFRP-2, sFRP-4, sFRP-5, WIF-1, and Dkk-3, compared to healthy controls.